INVESTIGATION OF THE ANTI-TUMOR EFFECTS OF BEVACIZUMAB ON GLIOBLASTOMA CELLS

Abstract

Aim: Glioblastoma multiforme (GBM) is the most malignant glial tumor. Angiogenesis which providesnutrient and oxygen support to proliferating cells plays an essential role in GBM development,proliferation, and metastasis. The development of antiangiogenetic agents is a promising treatmentapproach as blood vessels are essential for the vitality of tumor cells. For this purpose, in this study, theeffects of bevacizumab on cell viability and apoptosis were analyzed using glioblastoma cells.Material and method: U-87 MG and T98G cells were treated with various concentrations of bevacizumabfor 24 hours, 48 hours, and 72 hours. Cell viability was analyzed after administration of bevacizumab.Cytotoxicity was determined using MTT. Apoptosis rate was determined with cell death detection kit.Results: Cell viability analysis showed that when 8 mg / ml bevacizumab was administered toglioblastoma cells for 48 hours and 72 hours, cell proliferation was only 50% compared to proliferation ofcells without bevacizumab. Additionally, apoptosis rates for U-87 MG and T98G cell lines treated withvarious concentrations of bevacizumab for 48 hours and 72 hours showed results similar to those of cellviability.Conclusions: This study showed that while high concentration treatment of U-87 MG cells caused anincrease in cell viability in a time-dependent manner, high dose treatment of T98G cells resulted in adecrease in cell viability in a time-dependent manner. This means that some glioblastoma cells can stillsurvive under high doses of bevacizumab. This, in turn, demonstrated that glioblastoma cells developedresistance against bevacizumab.